246 results on '"Colombatto, Piero"'
Search Results
2. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy
3. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study
4. Highly dynamic changes of regional HBV epidemiology over two decades
5. WED-446 Safety of direct-acting antivirals for hepatitis C infection and direct oral anticoagulants co-administration: an italian multicentric study
6. SAT-245 Semaglutide for type 2 diabetes control in metabolic dysfunction-associated steatotic liver disease (MASLD): a two-way effect?
7. WED-314-YI Head-to-head comparison of two different ultrasound systems to measure the liver attenuation parameter
8. FRI-014 Comparison of two ultrasound diagnostic systems for measuring liver stiffness in clinical practice
9. Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection
10. Impact of baseline gadoxetic acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study
11. Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID‐19 pandemic.
12. Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration.
13. Hepatic adrenal rest tumor in a patient with multifactorial liver cirrhosis: a case report with CT and MRI findings and pathologic correlation
14. The Circulating miRNA Profile of Chronic Hepatitis D and B Patients Is Comparable but Differs from That of Individuals with HBeAg-Negative HBV Infection
15. Simple proxies of insulin resistance identify obese metabolic dysfunction‐associated fatty liver disease subjects with advanced liver disease
16. Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence
17. Shortcomings of “FIB-4 First” strategy in screening for non-alcoholic fatty liver disease (NAFLD) patients at risk for disease progression in a real life setting: will we be detracting therapeutic opportunities from patients?
18. Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy
19. HDV RNA levels <1000 IU/ml and total anti-HDV titers <1:1000 identify chronic hepatitis D subjects without active liver disease
20. Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy
21. Techniques of parenchyma-sparing hepatectomy for the treatment of tumors involving the hepatocaval confluence: A reliable way to assure an adequate future liver remnant volume
22. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel
23. Simple proxies of insulin resistance identify obese metabolic dysfunction‐associated fatty liver disease subjects with advanced liver disease.
24. Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging
25. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B:A multicentre cohort study
26. A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C
27. Modeling the Dynamics of HCV Infected Cells to Tailor Antiviral Therapy in Clinical Practice: Can This Approach Fit for Neoplastic Cells?
28. Highly dynamic changes of regional HBV epidemiology over two decades
29. Stauffer syndrome in a tumor of the pancreatic tail: A paracrine pathogenesis, rather than an inflammatory disimmune phenomenon – a case report
30. HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
31. Benign course of HBV reactivations during DAAs in untreated ENI with HBV-HCV co-infections correlates with different HBsAg kinetics compared to NAs treated CHB patients
32. Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line
33. Case Report: MIS-C With Prominent Hepatic and Pancreatic Involvement in a Vaccinated Adolescent – A Critical Reasoning
34. Long‐term outcome of inactive and active, low viraemic HBeAg‐negative‐hepatitis B virus infection: Benign course towards HBsAg clearance
35. Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
36. Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
37. Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers
38. Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib
39. MR imaging features of multiple biliary hamartomas (Von Meyenburg Complex): A pictorial review and differential diagnosis
40. SAT-148 - Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy
41. WED-157 - HDV RNA levels
42. SAT-456 - Shortcomings of “FIB-4 First” strategy in screening for non-alcoholic fatty liver disease (NAFLD) patients at risk for disease progression in a real life setting: will we be detracting therapeutic opportunities from patients?
43. Oral administration of gentamicin for prophylaxis of KPC-producing Klebsiella pneumoniae gut colonization in patients treated with a novel parenchymal-sparing liver surgery: the GEN Gut study
44. PTFE Graft as a “Bridge” to Communicating Veins Maturation in the Treatment of an Intrahepatic Cholangiocarcinoma Involving the 3 Hepatic Veins. The Minor-but-Complex Liver Resection
45. Steatosis/steatohepatitis: how sustainable is the non-invasive instrumental differential diagnosis in clinical practice?
46. Modeling the Dynamics of HCV Infected Cells to Tailor Antiviral Therapy in Clinical Practice: Can This Approach Fit for Neoplastic Cells?
47. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
48. History and outcome of hepatocellular carcinoma depend on etiology of chronic liver disease: a 10 years single center cohort study: 611
49. Three HBsAg kinetic profiles in HBeAg negative infection and chronic hepatitis are associated with different chances of HBsAg clearance
50. Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.